Data Type
Cell Information
(855)
Citations
(4778)
FAQ
(701)
Culture Media
(92)
Category
Primary Cells and Media
(271)
Transfection
(183)
Laboratory Instrumentation
(71)
Electrophoreses and Analysis
(56)
Endotoxin Detection
(56)
Bioassay
(47)
3D Cell Culture
(42)
Mycoplasma Detection and Prevention
(33)
Serum-free and Speciality Media
(15)
Classical Media and Reagents
(11)
Cell Lines and Primary Cancer Cells
(9)
Live Cell Imaging
(8)
Uncategorized
(7)
Cell Services
(3)
Bioprocess Containers
(1)
Protozoa
(1)
+ Show All
Research Area
Uncategorized
(174)
Basic Research
(128)
Cancer Research/Cell Biology
(85)
Immunotherapy / Hematology
(71)
Endotoxin Testing
(55)
Stem Cells
(53)
Molecular Biology
(40)
Neurobiology
(38)
Toxicology
(33)
Respiratory Research
(32)
Cardiovascular
(28)
Regenerative medicine
(24)
Dermatology/Tissue Engineering
(21)
Gene Expression
(15)
Drug Discovery
(7)
Gastroenterology
(4)
Parasitology
(3)
+ Show All
701 results sorted by
relevance
alphabetical
newest first
oldest first
I
s
t
h
e
a
g
e
o
f
t
h
e
m
i
c
e
i
m
p
o
r
t
a
n
t
f
o
r
m
y
m
o
u
s
e
T
c
e
l
l
N
u
c
l
e
o
f
e
c
t
i
o
n
™
?
Yes. We recommend using mice between 6-12 weeks. Using mouse T cells isolated from younger or older animals for Nucleofection™ may result in much lower transfection efficiencies and/or viabilities.
D
o
e
s
t
h
e
r
e
c
o
v
e
r
y
m
e
d
i
u
m
c
o
n
t
a
i
n
e
d
i
n
t
h
e
M
o
u
s
e
T
C
e
l
l
N
u
c
l
e
o
f
e
c
t
o
r
™
K
i
t
s
c
o
n
t
a
i
n
a
n
y
i
m
m
u
n
o
g
e
n
i
c
s
u
b
s
t
a
n
c
e
s
?
No. The post Nucleofection™ Recovery media contains no immunogenic factors and should not influence cell stimulation or differentiation. For Mouse T cells, some experiments have shown that after Nucleofection™ cells can be stimulated efficiently in...
I
s
e
e
a
c
t
i
v
a
t
i
o
n
o
f
m
y
m
o
n
o
c
y
t
e
s
(
o
r
m
a
c
r
o
p
h
a
g
e
s
o
r
D
C
s
)
f
o
l
l
o
w
i
n
g
N
u
c
l
e
o
f
e
c
t
i
o
n
™
.
W
h
y
i
s
t
h
i
s
?
W
h
a
t
c
a
n
I
d
o
t
o
a
d
d
r
e
s
s
t
h
i
s
p
r
o
b
l
e
m
?
We have examined the effects of Nucleofection™ (without DNA) on these cells and have not observed significant activation. This indicates that neither the Nucleofector™ Solution, the Nucleofector™ Program nor the recovery medium are sufficient for...
C
a
n
I
u
s
e
a
N
u
c
l
e
o
f
e
c
t
o
r
™
I
o
r
N
u
c
l
e
o
f
e
c
t
o
r
™
2
b
D
e
v
i
c
e
t
o
g
e
t
h
e
r
w
i
t
h
t
h
e
9
6
-
w
e
l
l
S
h
u
t
t
l
e
™
D
e
v
i
c
e
?
No, the 96-well Shuttle™ only works in conjunction with the Nucleofector™ IIs Device or our 4D-Nucleofector™ Device.
I
o
b
s
e
r
v
e
d
h
i
g
h
m
o
r
t
a
l
i
t
y
r
a
t
e
s
i
n
m
E
S
c
e
l
l
s
a
f
t
e
r
N
u
c
l
e
o
f
e
c
t
i
o
n
™
w
i
t
h
a
C
r
e
r
e
c
o
m
b
i
n
a
s
e
e
x
p
r
e
s
s
i
o
n
v
e
c
t
o
r
.
H
o
w
c
a
n
I
i
n
c
r
e
a
s
e
t
h
e
v
i
a
b
i
l
i
t
y
?
The High mortality after transfection might be due to the Cre recombinase itself, because the mammalian genome contains pseudo loxP sites (Thyagarajan B et al. (2000) Mammalian genomes contain active recombinase recognition sites. Gene....
I
s
i
t
p
o
s
s
i
b
l
e
t
o
u
s
e
d
i
f
f
e
r
e
n
t
s
u
b
s
t
r
a
t
e
s
(
e
.
g
.
s
i
R
N
A
d
u
p
l
e
x
e
s
)
w
i
t
h
t
h
e
9
6
-
w
e
l
l
S
h
u
t
t
l
e
™
D
e
v
i
c
e
?
Yes. Transfection can be done with any substrate AND under exactly the same conditions. For example, the same conditions (96-well Shuttle™ Solution and program) are used for siRNA transfection or shRNA vectors. This greatly facilitates the...
W
h
a
t
i
s
t
h
e
a
d
v
a
n
t
a
g
e
o
f
t
h
e
9
6
-
w
e
l
l
S
h
u
t
t
l
e
™
D
e
v
i
c
e
o
v
e
r
c
o
m
m
o
n
l
i
p
o
f
e
c
t
i
o
n
,
e
s
p
e
c
i
a
l
l
y
i
n
a
h
i
g
h
t
h
r
o
u
g
h
p
u
t
f
r
a
m
e
w
o
r
k
?
Several primary cells of high research relevance can simply not be transfected at relevant efficiencies and viabilities using lipofection. The same holds true for many suspension cell lines which are often used for protein production. These difficult...
W
h
a
t
a
r
e
t
h
e
c
o
n
t
e
n
t
s
o
f
a
9
6
-
w
e
l
l
S
h
u
t
t
l
e
™
K
i
t
?
As the system will most likely be used for high-throughput approaches we provide plates which are pre-equipped with 96-well Nucleocuvette™ modules (2x8). In addition to that, the 96-well Shuttle solution, the supplement, and the pmaxGFP™ are also...
W
h
a
t
i
s
t
h
e
a
d
v
a
n
t
a
g
e
o
f
t
h
e
N
u
c
l
e
o
f
e
c
t
o
r
™
T
e
c
h
n
o
l
o
g
y
o
v
e
r
c
o
m
m
o
n
e
l
e
c
t
r
o
p
o
r
a
t
i
o
n
(
s
y
s
t
e
m
s
)
?
High cell viability and high transfection efficiency with the Nucleofection™ Technology are the most prominent features. Nucleofection™, i.e., the transfer of DNA into the nucleus and not only the cytosol, is essential when working with non-dividing...
C
a
n
L
o
n
z
a
'
s
a
n
t
i
b
i
o
t
i
c
s
b
e
u
s
e
d
i
n
c
l
i
n
i
c
a
l
t
r
i
a
l
s
?
No. They are for research purposes only.
PREVIOUS
PAGE
1
PAGE
2
PAGE
3
PAGE
4
PAGE
5
PAGE
6
PAGE
7
PAGE
8
PAGE
9
NEXT